Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
Susan Mayor Analysis of the outcome of mammography screening in Sweden over
the past 10 years has shown no significant reduction in mortality from
breast cancer.
The study analysed data from 17 county councils in Sweden that
introduced mammography screening in the late 1980s. The results showed
an overall reduction in breast cancer mortality of 0.8%when the number
of observed deaths was compared with those expected during the period
1986 to 1996 (L kartidningen 1999;96:904). More than 600000 women aged
50 to 69 years were included in the study.
A member of the research team, Dr Gïran Sjïnell, a general
practitioner in Stockholm, commented: "Our main finding was
surprising-10 years' observation in a huge population of women
undergoing screening showed no sign of a reduction in mortality from
breast cancer." He contrasted this with clinical trials supporting
screening, showing up to 30%reductions in mortality. "We think that
the findings illustrate the difference between trial conditions and
real clinical practice. Perhaps the trials included slightly different
populations or may have been stopped after significance had been
reached, failing to look at longer term effects."
The researchers warned that the screening programme had led to
considerable numbers of women being given a false positive diagnosis
and undergoing unnecessary biopsy. Nearly 100000 of the women in the
study had received a false positive diagnosis. Of these, approximately
16000 had undergone biopsy, and more than 4000 women underwent breast
surgery, including mastectomy. "Women should be warned about the
potentially negative consequences of screening," suggested Dr
Sjïnell. He pointed out, however, that the new research does not in
any way question the use of mammography for diagnosing breast cancer.
Other breast cancer screening specialists have argued that breast
cancer screening is worth while. Michael Dixon, an honorary senior
lecturer at the Edinburgh Breast Unit, Scotland, said: "The science
for mammographic screening for breast cancer is very sound. In fact,
the new findings are easily explainable. Experience elsewhere has shown
that there is a long lag between initiating a breast screening
programme and reaching a level of detection that will reduce
mortality." He explained that radiologists taking part in trials of
mammography screening-which have shown high rates of breast cancer
detection-are generally highly skilled and experienced. "When
screening is opened up to national programmes a much larger population
of radiologists is involved. Inevitably, it takes some time for them to
climb up the learning curve in accurately detecting abnormalities,"
said Mr Dixon.
The national coordinator for the NHS Breast Screening Programme,
Julietta Patnick, agreed: "Last year was the first year that we
matched the UK national breast screening programme matched trial
results in detecting cancers. This took nine to ten years to
achieve."

After 10 years of mammography, breast cancer deaths were not
reduced
© BMJ 1999
Read all Rapid Responses
Israeli students are refusing to perform intimate examinations on anaesthetised women without their informed consent.